Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease

International Journal of Cardiology

Volumn 156, Issue 3, 2012, Pages 289-294

  Wolf, Christian ^a,b   Lorenzen, Johan M ^a   Stein, Sylvia ^a,b   Tsikas, Dimitrios ^a   Störk, Stefan ^b   Weidemann, Frank ^b   Ertl, Georg ^b   Anker, Stefan D ^c,d   Bauersachs, Johann ^a   Thum, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Asymmetric dimethylarginine; Coronary artery disease; Dimethylamine

Indexed keywords

DIMETHYLAMINE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; AMINO ACID URINE LEVEL; ANALYTICAL PARAMETERS; ARTICLE; ASYMMETRIC DIMETHYLARGININE CREATININE RATIO; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE URINE LEVEL; DIMETHYLAMINE ASYMMETRIC DIMETHYLARGININE RATIO; DISEASE SEVERITY; FEMALE; HEART CATHETERIZATION; HEART FUNCTION; HUMAN; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MORTALITY; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ARGININE; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84859801276     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.11.003     Document Type: Article

References (32)

1. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res 2009;60(6):448-60.
2. Perticone F, Sciacqua A, Maio R, et al. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol 2010;142(3):236-41.
3. Garcia RG, Perez M, Maas R, et al. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol 2007;122(2):176-8. (Pubitemid 47552581)
4. Cooke JO. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000;20(9):2032-7.
5. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005;46(9):1693-701. (Pubitemid 41531624)
6. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003;59(4):824-33 Review. (Pubitemid 38366238)
7. Fleissner F, Jazbutyte V, Fiedler J, et al. Asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a MicroRNA-21-dependent mechanism. Circ Res 2010;107(1):138-43.
8. Goette A, Wolfram O, Jentsch-Ullrich K, et al. The effects of G-CSF-induced mobilization of progenitor cells are limited by ADMA. Int J Cardiol; 2009. Mar 19. [Electronics publication ahead of print].
9. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from AtheroGene study. Circulation 2005;97:e53-9.
10. Lenzen H, Tsikas D, Boger RH. Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study. Eur J Clin Pharmacol 2006;62(Suppl 13):45-9.
11. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 2004;134(10 Suppl):2842 S-7 S.
12. Maas R, Quitzau K, Schwedhelm E, et al. Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. Atherosclerosis 2007;191(1):211-9. (Pubitemid 46227420)
13. Tran CTL, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003;4(4):33-40. (Pubitemid 38234493)
14. Feng M, He ZM, Zhu YX, et al. Improvement of endothelial dysfunction in atherosclerotic rabbit aortas by ex vivo gene transferring of dimethylarginine dimethylaminohydrolase-2. Int J Cardiol; 2010. May 10. [Epub ahead of print].
15. Krempl TK, Maas R, Sydow K, et al. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005;26(18):1846-51. (Pubitemid 41253296)
16. Maas R, Wenske S, Zabel M, et al. Elevation of asymmetrical dimethylarginine (ADMA) and coronary artery disease in men with erectile dysfunction. Eur Urol 2005;48:1004-11 discussion 1011-2.
17. Tsikas D, Thum T, Becker T, et al. Accurate quantification of dimethylamine (DMA) in human urine by gas chromatography-mass spectrometry as pentafluorobenzamide derivative: evaluation of the relationship between DMA and its precursor asymmetric dimethylarginine (ADMA) in health and disease. J Chromatogr B 2007;851(1-2):229-39. (Pubitemid 46720136)
18. Tsikas D, Schubert B, Gutzki FM, Sandmann J, Frolich JC. Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative. J Chromatogr B 2003;798(1):87-99. (Pubitemid 37421285)
19. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23(8):1455-9. (Pubitemid 36994536)
20. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 2004;134(10 Suppl):2842 S-7 S discussion 2853S.
21. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16(8):2456-61. (Pubitemid 41725064)
22. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003;4(4):41-51. (Pubitemid 38234494)
23. Kielstein JT, Tsikas D, Fliser D. Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006;62(Suppl 13):39-44.
24. Cavusoglu E, Ruwende C, Chopra V, et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis 2010;210(1):226-31.
25. Bae SW, Stuhlinger MC, Yoo HS, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005;95(6):729-33. (Pubitemid 40332650)
26. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002 Feb;13(2):490-6. (Pubitemid 34106292)
27. Schnog JB, Teerlink T, van der Dijs FP, et al. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol 2005;84(5):282-6. (Pubitemid 41166821)
28. Schulze F, Maas R, Freese R, et al. Determination of a reference value for N(G), N (G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005;35(10):622-6. (Pubitemid 41406726)
29. Carpeggiani C, Landi P, Michelassi C, et al. Long-term prognosis in stable angina; medical treatment or coronary revascularization in patients younger than 70 years? Int J Cardiol; 2009. Nov 11.
30. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Interv Trial unstable Angina Lancet 2002;360(9335):743-51.
31. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007;53(2):273-83. (Pubitemid 46338272)
32. Shewan LG, Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.